Iterum Therapeutics appoints Joseph Whalen to board; David Kelly named Chairman

Iterum Therapeutics plc

Joseph J. Whalen appointed as Class III director effective March 10, 2025; term expires at 2027 AGM.
Whalen joins Audit and Compensation Committees; receives annual cash retainers of $35,000 (board), $7,500 (audit), $6,000 (compensation).
David Kelly appointed Chairman of the Board effective March 10, 2025, after Ronald Hunt resigned on February 14, 2025.
Whalen's appointment restores Audit Committee to three independent members, regaining Nasdaq Listing Rule 5605(c)(2)(A) compliance.

item 5.02 item 8.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000950170-25-035943
form_type: 8-K
ticker: ITRMF
cik: 0001659323
company_name: Iterum Therapeutics plc
filed_at: 2025-03-10T23:59:59+00:00
discovered_at: 2026-05-14T18:03:04.343635+00:00
generated_at: 2026-05-25T01:36:21.998052+00:00
sec_items: ["5.02", "8.01"]
event_type: leadership
sentiment: neutral
materiality_score: 0.4
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000950170-25-035943
json_url: https://secwatch.observer/filing/0000950170-25-035943.json
markdown_url: https://secwatch.observer/filing/0000950170-25-035943.md
text_url: https://secwatch.observer/filing/0000950170-25-035943.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1659323/000095017025035943/0000950170-25-035943-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1659323/000095017025035943/itrm-20250307.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Joseph J. Whalen

Class III Director

ITRMF · Iterum Therapeutics plc

Effective: 2025-03-10
Filed: Mar 10, 2025 23:59 UTC

approved the appointment of Joseph J. Whalen as a member of the Board, effective as of March 10, 2025.

Role change

David Kelly

Chairman of the Board

ITRMF · Iterum Therapeutics plc

Effective: 2025-03-10
Filed: Mar 10, 2025 23:59 UTC

the Board also appointed David Kelly, an existing director of the Board, as Chairman of the Board, effective as of March 10, 2025.

Source-grounded claims

aca580e0fc

Joseph J. Whalen was appointed as Class III Director at Iterum Therapeutics plc.

approved the appointment of Joseph J. Whalen as a member of the Board, effective as of March 10, 2025.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

dd3bddcdb1

David Kelly was appointed as Chairman of the Board at Iterum Therapeutics plc.

the Board also appointed David Kelly, an existing director of the Board, as Chairman of the Board, effective as of March 10, 2025.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

Source: SEC EDGAR

accession 0000950170-25-035943

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.